Brief: Bayer Phase III Prostate Cancer Trial Cuts Metastasis Or Death Risk 58%

Bayer AG

24/10/2026 07:30

Oct 24 (Reuters) - BAYER AG BAYGn.DE:
PHASE III DASL-HICAP TRIAL MET PRIMARY ENDPOINT OF METASTASIS-FREE SURVIVAL
DAROLUTAMIDE PLUS ADT AND RADIATION THERAPY REDUCED RISK OF METASTASIS OR DEATH BY 58% IN PHASE III PROSTATE CANCER TRIAL
FOUR-YEAR METASTASIS-FREE SURVIVAL RATE REACHED 95% WITH DAROLUTAMIDE VERSUS 88% WITH PLACEBO
       
Further company coverage: [BAYGn.DE] 
     
     
     

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))